Improved Clinical Outcomes After FDG-PET Diagnosis Key To Coverage – CMS
This article was originally published in The Gray Sheet
Executive Summary
CMS' decision to deny Medicare coverage of FDG-PET for soft tissue sarcoma and most thyroid cancer indications is consistent with the MCAC recommendation that standards of evidence should not be relaxed for diagnostics of rare diseases
You may also be interested in...
AHRQ Brain Tumor MRS Tech Assessment Makes NCD Reversal Doubtful
The limited availability of magnetic resonance spectroscopy (MRS) for diagnosing brain tumors has made it difficult to pursue the types of large clinical trials necessary for obtaining national coverage, according to an 1AHRQ tech assessment
AHRQ Brain Tumor MRS Tech Assessment Makes NCD Reversal Doubtful
The limited availability of magnetic resonance spectroscopy (MRS) for diagnosing brain tumors has made it difficult to pursue the types of large clinical trials necessary for obtaining national coverage, according to an 1AHRQ tech assessment
CMS Agrees With Industry: PET Coverage Process Should Be Overhauled
Medical imaging equipment manufacturers should play a more active role in the development of Medicare coverage policies for diagnostic imaging technologies, CMS Coverage & Analysis Director Steve Phurrough said May 7 at an AdvaMed meeting on Medicare policy in Baltimore